Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupiter, Florida.
| Revenue (TTM) | 64,690 |
| Gross Profit (TTM) | $-1.82M |
| EBITDA | — |
| Operating Margin | -11313.00% |
| Return on Equity | -1889.00% |
| Return on Assets | -159.60% |
| Revenue/Share (TTM) | $0.13 |
| Book Value | $-0.55 |
| Price-to-Book | 227.66 |
| Price-to-Sales (TTM) | 59.21 |
| EV/Revenue | 64.04 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.32M |
| Float | 564,080 |
| % Insiders | 29.96% |
| % Institutions | 2.25% |
Volatility is currently expanding
First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences' Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson's Disease
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson's disease program
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced today that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 09:00 AM ET at the historic Bank of New York.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JUNS and any ticker you trade — then tracks every position and per-strategy win rate.
